2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Integrated therapy for Functional Movement Disorders: results from a pilot clinic

S. Lidstone, L. Macgillivray, C. Marras, M. Josef, L. Muc, A. Lang (Toronto, ON, Canada)

Functional (Psychogenic) Movement Disorders  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Intermediate CAG repeat length in the HTT gene and comorbidity – The SHAPE Study (Swedish-Huntingtin-Alleles-and-PhenotypE)

M. Ghazarian, E. Stattin, J. Sundblom, V. Niemelä (Uppsala, Sweden)

Huntington’s Disease  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Internal pallidum stimulation reduces mobile generalized dystonia in Wilson’s disease

S. Paschen, A. Helmers, J. Volkmann, G. Deuschl, D. Berg, KE. Zeuner (Kiel, Germany)

Rare Genetic and Metabolic Diseases  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Freezing of Gait After Deep Brain Stimulation in Parkinson’s Disease

B. González, S. Jauma, R. Gomez, C. Marzal, M. Calopa (Hospitalet de Llobregat, Spain)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

INTREPID: A 2-Year Follow-Up of a Prospective, Double Blinded, Multi-Center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant-Current Rechargeable System for Treatment of Parkinson’s Disease

J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Intronic pentanucleotide TTTCA repeat insertions do not cause familial and sporadic cortical myoclonic tremor with epilepsy in the UK

WY. Yau, H. Houlden (London, United Kingdom)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Investigating the impact of a-synuclein pathology on human embryonic stem cell derived dopaminergic neurons transplanted in an accelerated a-synuclein rat model of Parkinson’s disease

D. Hoban, S. Shrigley, L. Breger, J. Nelander Wahlestedt, T. Cardoso, B. Mattsson, K. Luk, M. Parmar, A. Björklund (Lund, Sweden)

Gene and Cell-Based Therapies  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Investigation into the causes of reduced caffeine levels in Parkinson’s disease

MI. de Bartolo, G. Leodori, A. Fabbrini, M. Costanzo, D. Belvisi, A. Conte, S. Manetto, A. Ciogli, C. Villani, A. Berardelli, G. Fabbrini (Rome, Italy)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

Investigation of the protective efficacy of alpha-synuclein-specific antibodies in a novel neuronal cell model for synucleinopathies

A. Peukert, M. Höllerhage, W. Zago, G. Höglinger (Munich, Germany)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

Involuntary movements with abnormal brain imaging: A Case Report

W. Webb, P. Chapman, V. Sung, M. Dean (Birmingham, AL, USA)

Huntington’s Disease  ·  Agora 3 West, Level 3